Prothena Corp. (NASDAQ:PRTA) was down 3.3% during mid-day trading on Monday following insider selling activity. The stock traded as low as $51.80 and last traded at $51.80, with a volume of 254,030 shares trading hands. The stock had previously closed at $53.55.

Specifically, insider Arthur W. Homan sold 3,125 shares of the company’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $52.16, for a total transaction of $163,000.00. Following the completion of the transaction, the insider now directly owns 3,125 shares of the company’s stock, valued at $163,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Arthur W. Homan sold 9,375 shares of the company’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $52.14, for a total transaction of $488,812.50. Following the transaction, the insider now directly owns 9,375 shares of the company’s stock, valued at $488,812.50. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Several equities analysts have recently commented on PRTA shares. Credit Suisse Group AG reaffirmed a “buy” rating and set a $65.00 price objective on shares of Prothena Corp. in a research note on Sunday, September 11th. Zacks Investment Research downgraded shares of Prothena Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, October 4th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a research note on Wednesday, June 22nd. Wedbush reaffirmed an “outperform” rating and set a $77.00 price objective on shares of Prothena Corp. in a research note on Monday, September 26th. Finally, Barclays PLC upped their price objective on shares of Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $76.80.

The stock’s 50-day moving average is $57.27 and its 200 day moving average is $49.19. The company’s market cap is $1.77 billion.

Prothena Corp. (NASDAQ:PRTA) last released its earnings results on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.91) by $0.27. The company had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.39 million. Prothena Corp. had a negative return on equity of 28.15% and a negative net margin of 8,628.11%. Prothena Corp.’s revenue was up 22.2% on a year-over-year basis. On average, equities analysts forecast that Prothena Corp. will post ($4.25) EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in PRTA. BlackRock Inc. boosted its stake in shares of Prothena Corp. by 197.8% in the first quarter. BlackRock Inc. now owns 2,656 shares of the company’s stock valued at $110,000 after buying an additional 1,764 shares during the last quarter. Societe Generale acquired a new stake in shares of Prothena Corp. during the second quarter valued at approximately $111,000. BNP Paribas Arbitrage SA boosted its stake in shares of Prothena Corp. by 49.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,039 shares of the company’s stock valued at $141,000 after buying an additional 1,344 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Prothena Corp. by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 4,021 shares of the company’s stock valued at $141,000 after buying an additional 493 shares during the last quarter. Finally, Emerald Acquisition Ltd. acquired a new stake in shares of Prothena Corp. during the second quarter valued at approximately $195,000.

Prothena Corp. Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

5 Day Chart for NASDAQ:PRTA

Receive News & Stock Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related stocks with our FREE daily email newsletter.